Companies/SciBase Holding AB
Follow

SciBase Holding AB

Nasdaq First North GM Stockholm (Sweden)

SciBase is a medical technology company that develops devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. Its first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. The Company operates in two segments: skin cancer and skin barrier assessment.
Go to market

Sector:
HEALTH CARE
>
Medical Devices
Healthcare
Media
www.scibase.com
Rights issue
Price
1.55 SEK
Subscription period
07 Mar - 21 Mar 2023
Subscribe
Please to proceed or
Sign up for FREE
 View Details
Top
News
SciBase offentliggör prospekt i samband med fullt garanterad företrädesemission
02 Mar 2023 - 10:45
SciBase publishes prospectus in connection with fully guaranteed rights issue
02 Mar 2023 - 10:45
SciBase beslutar om en fullt garanterad företrädesemission om cirka 79,6 MSEK
13 Feb 2023 - 08:45
SciBase resolves on a fully guaranteed rights issue of approximately SEK 79.6 million
13 Feb 2023 - 08:45
Bokslutskommuniké
13 Feb 2023 - 08:00
Year-end report
13 Feb 2023 - 08:00
Letter from the CEO
22 Dec 2022 - 08:00
Nevisense för hudbarriärutvärdering ingår i stor australiensisk födelsekohortstudie
15 Dec 2022 - 08:00
Nevisense for skin barrier evaluation included in large Australian birth cohort study
15 Dec 2022 - 08:00
SciBase invitation to a webinar on November 10 at 11:00 CET
08 Nov 2022 - 15:00
SciBase bjuder in till webinar den 10 november klockan 11:00 CET
08 Nov 2022 - 15:00
SciBase VD Simon Grant kommenterar samarbetet med Johnson & Johnson Consumer Health
08 Nov 2022 - 09:00
SciBase CEO Simon Grant gives a comment regarding the collaboration with Johnson & Johnson Consumer Health
08 Nov 2022 - 09:00
SciBase tillkännager samarbete för att upptäcka dysfunktion av hudbarriären hos spädbarn
07 Nov 2022 - 16:30
SciBase announces collaboration to detect skin barrier dysfunction in infants
07 Nov 2022 - 16:30
Ny artikel diskuterar EIS som ett potentiellt kliniskt mått på hudbarriärens integritet
27 Oct 2022 - 08:00
New article discusses EIS as a potential clinical measure of skin barrier integrity
27 Oct 2022 - 08:00
New study shows Nevisense significantly improves US clinician’s decision-making beyond dermoscopy
26 Oct 2022 - 08:00
Ny studie visar att Nevisense signifikant förbättrar amerikanska läkares beslutfattande utöver beslut baserade på dermatoskop
26 Oct 2022 - 08:00
Följande personer har utsetts att ingå i SciBase Holdings valberedning inför årsstämman 2023:
07 Oct 2022 - 14:00
The following people have been appointed as members of SciBase Holding’s nominating committee for the Annual General Meeting in 2023:
07 Oct 2022 - 14:00
Nevisense detects skin barrier damage in mice caused by household detergents
01 Sep 2022 - 08:00
Nevisense detekterar skador på hudens barriär hos möss orsakade av tvättmedel
01 Sep 2022 - 08:00
Delårsrapport
18 Aug 2022 - 08:00
Interim report
18 Aug 2022 - 08:00
FDAs expertpanels rekommendation i linje med SciBase – behåll högsta kraven för godkännande av alla nya instrument för att analysera hudlesioner
09 Aug 2022 - 08:00
FDA expert panel in line with SciBase position to keep stringent approval level for all new skin lesion analyzers
09 Aug 2022 - 08:00
Årsstämma har hållits i SciBase Holding AB (publ)
18 May 2022 - 14:15
Annual general meeting has been held in SciBase Holding AB (publ)
18 May 2022 - 14:15
US study shows that EIS and Nevisense significantly improves clinicians’ diagnostic accuracy
16 May 2022 - 08:00
Amerikansk studie visar att EIS och Nevisense signifikant förbättrar läkares diagnostiska noggrannhet
16 May 2022 - 08:00
Delårsrapport
12 May 2022 - 08:00
Interim report
12 May 2022 - 08:00
SciBase to present at the Redeye Medtech & Diagnostics Seminar on May 11, 2022
10 May 2022 - 08:00
SciBase kommer presentera vid Redeye Medtech & Diagnostics Seminar den 11 maj, 2022
10 May 2022 - 08:00
Tysk studie visar på kliniska nyttan med Nevisense
29 Apr 2022 - 15:30
German study shows clinical benefit of Nevisense
29 Apr 2022 - 15:30
SciBase publishes the Annual report for 2021
22 Apr 2022 - 09:00
SciBase publicerar årsredovisning för 2021
22 Apr 2022 - 09:00
Kallelse till årsstämma i SciBase Holding AB (publ)
13 Apr 2022 - 13:00
1 2 3 4 5
Show

40

Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Show archived

NB! Information about past events and all documents are available for signed in users who have bought those events.

Type
Ticker
ISIN
Market
SHARE
SCIB
SE0007045414
Nasdaq First North GM Stockholm
Sweden (SE)
Details of share in SciBase Holding AB with ticker SCIB
Status
Active
Currency
SEK
First trading date
02 Jun 2015
Rights issue
Sign in to buy
Rights issue
Sign in to buy
Exercise
Sign in to buy
Directed issue
Sign in to buy
Directed issue
Sign in to buy
Type
Price
Pre-money
Time
Files
Rights issue
1.55 SEK
106.55M SEK
07 Mar - 21 Mar 2023
Share issue in SciBase Holding AB

We have reserved some of the more detailed information for our registered users. Please sign in if You have already registered.

Get access to Events, Instruments, Documents, Media and much more by signing up for FREE!

Partially obscured image showing event data
Sign up for FREE
Type
Ticker
ISIN
Market
SHARE
SCIB
SE0007045414
Nasdaq First North GM Stockholm
Sweden (SE)
Details of share in SciBase Holding AB with ticker SCIB
Status
Active
Currency
SEK
First trading date
02 Jun 2015
Rights issue
Sign in to buy
Rights issue
Sign in to buy
Directed issue
Sign in to buy
Directed issue
Sign in to buy
Type
Price
Pre-money
Time
Files
Rights issue
1.55 SEK
106.55M SEK
07 Mar - 21 Mar 2023
Share issue in SciBase Holding AB

We have reserved some of the more detailed information for our registered users. Please sign in if You have already registered.

Get access to Events, Instruments, Documents, Media and much more by signing up for FREE!

Partially obscured image showing event data
Sign up for FREE
Type
Ticker
ISIN
Market
OPTION
SCIB TO 1
SE0014399689
Nasdaq First North GM Stockholm
Sweden (SE)
Details of option in SciBase Holding AB with ticker SCIB TO 1
Status
Archived
Currency
SEK
Trading period
10 Jun 2020 - 14 Oct 2020
Terms
One (1) warrant entitles the holder to subscribe for one (1) new share in the Company for the price which corresponds to seventy (70) percent of the volume weighted the average payment price for the Company's share on the Nasdaq First North Growth Market for a period of ten (10) trading days immediately preceding September 30, 2020 (including September 30, 2020), but at least SEK 1 and maximum SEK 1.75 per share. The warrants will be issued free of charge and will be exercisable for subscription of new shares during the period October 5, 2020 until October 16, 2020.
Update (02.10.2020): Exercise price for warrants of series TO1 in SciBase Holding AB determined and the subscription period commence on 5 October 2020.
Exercise
Sign in to buy
People
Simon James Grant
CEO
Tord Bertil Lendau
Chairman of the board
Diana Ferro
Board member
Thomas Taapken
Board member
Barbro Fridén
Board member
Jvalini Dwarkasing
Board member
Company Details
Sector
HEALTH CARE
Website
Address
Landsvägen 39
Zip code
172 63
City/district
Sundbyberg
Country
Sweden (SE)
Phones
Email
[email protected]
Registration number
556773-4768
LEI code
549300IY6ZWVN0V2P455
First trade date
02 Jun 2015
Registration date
18 Dec 2008
Short name
SCIB

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More